The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress

Cell Cycle

Volumn 12, Issue 24, 2013, Pages 3791-3803

  Kim, Ekaterina R ^a   Selyutina, Anastasia A ^a,b   Buldakov, Ilya A ^a   Evdokimova, Valentina ^a,c   Ovchinnikov, Lev P ^a   Sorokin, Alexey V ^a  

^a INSTITUTE OF PROTEIN RESEARCH   (Russian Federation)

^b UNIVERSITY OF TARTU   (Estonia)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Cleavage; DNA damage; DNA reparation; Drug resistance; Nuclear localization; PEST; Proteasome; Truncation; YB 1

Indexed keywords

20S PROTEASOME; DOXORUBICIN; DOXYCYCLINE; ETOPOSIDE; HISTONE H2AX; MRE11 PROTEIN; PROTEASOME; RAD50 PROTEIN; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CELL STRAIN 3T3; CELL SURVIVAL; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; GENE EXPRESSION; GENOTOXICITY; IMMUNOFLUORESCENCE MICROSCOPY; PROTEIN DNA INTERACTION;

CLEAVAGE; DNA DAMAGE; DNA REPARATION; DRUG RESISTANCE; NUCLEAR LOCALIZATION; PEST; PROTEASOME; TRUNCATION; YB-1;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL NUCLEUS; CELL PROLIFERATION; DNA; DNA DAMAGE; DNA REPAIR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; MICE; NIH 3T3 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; Y-BOX-BINDING PROTEIN 1;

EID: 84891840119     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26670     Document Type: Article

References (56)

1. Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc) 2011; 76:1402-33; PMID:22339596; http://dx.doi.org/10.1134/S0006297911130049
2. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci U S A 1988; 85:7322-6; PMID:3174636; http://dx.doi.org/10.1073/pnas.85.19.7322
3. Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K, Kuwano M. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997; 417:390-4; PMID:9409758; http://dx.doi.org/10.1016/S0014-5793(97)01296-9
4. Higashi K, Inagaki Y, Suzuki N, Mitsui S, Mauviel A, Kaneko H, Nakatsuka I. Y-box-binding protein YB-1 mediates transcriptional repression of human alpha 2(I) collagen gene expression by interferon-gamma. J Biol Chem 2003; 278:5156-62; PMID:12446674; http://dx.doi.org/10.1074/jbc.M208724200
5. Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S, Ono M, Izumi H, Kohno K, Sakai K, et al. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 2007; 26:2736-46; PMID:17072343; http://dx.doi.org/10.1038/sj. onc.1210084
6. Evdokimova V, Sorokin A. YBX1 (Y box binding protein 1). Atlas Genet Cytogenet Oncol Haematol 2011; 15:598-604
7. Evdokimova V, Ruzanov P, Anglesio MS, Sorokin AV, Ovchinnikov LP, Buckley J, Triche TJ, Sonenberg N, Sorensen PH. Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol 2006; 26:277-92; PMID:16354698; http://dx.doi.org/10.1128/MCB.26.1.277-292.2006
8. Evdokimova V, Ruzanov P, Imataka H, Raught B, Svitkin Y, Ovchinnikov LP, Sonenberg N. The major mRNA-associated protein YB-1 is a potent 5? cap-dependent mRNA stabilizer. EMBO J 2001; 20:5491-502; PMID:11574481; http://dx.doi.org/10. 1093/emboj/20.19.5491
9. Dolfini D, Mantovani R. YB-1 (YBX1) does not bind to Y/CCAAT boxes in vivo. Oncogene 2013; 32:4189-90; PMID:23160378; http://dx.doi.org/10.1038/onc. 2012.521
10. Tafuri SR, Wolffe AP. DNA binding, multimerization, and transcription stimulation by the Xenopus Y box proteins in vitro. New Biol 1992; 4:349-59; PMID:1622930
11. Swamynathan SK, Nambiar A, Guntaka RV. Role of single-stranded DNA regions and Y-box proteins in transcriptional regulation of viral and cellular genes. FASEB J 1998; 12:515-22; PMID:9576478
12. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004; 3:1485-92; PMID:15542787
13. Hasegawa SL, Doetsch PW, Hamilton KK, Martin AM, Okenquist SA, Lenz J, Boss JM. DNA binding properties of YB-1 and dbpA: binding to doublestranded, single-stranded, and abasic site containing DNAs. Nucleic Acids Res 1991; 19:4915-20; PMID:1923758; http://dx.doi.org/10.1093/nar/19.18.4915
14. Ise T, Nagatani G, Imamura T, Kato K, Takano H, Nomoto M, Izumi H, Ohmori H, Okamoto T, Ohga T, et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999; 59:342-6; PMID:9927044
15. Gaudreault I, Guay D, Lebel M. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res 2004; 32:316-27; PMID:14718551; http://dx.doi.org/10.1093/nar/ gkh170
16. Das S, Chattopadhyay R, Bhakat KK, Boldogh I, Kohno K, Prasad R, Wilson SH, Hazra TK. Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. J Biol Chem 2007; 282:28474-84; PMID:17686777; http://dx.doi.org/10.1074/jbc.M704672200
17. Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M, Kuwano M, Kohno K. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996; 56:4224-8; PMID:8797596
18. Bargou RC, Jürchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3:447-50; PMID:9095180; http://dx.doi.org/10.1038/nm0497-447
19. Stein U, Jürchott K, Walther W, Bergmann S, Schlag PM, Royer HD. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 2001; 276:28562-9; PMID:11369762; http://dx.doi.org/10.1074/jbc.M100311200
20. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G, Fietze E, Dietel M, Royer HD. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 2003; 278:27988-96; PMID:12695516; http://dx.doi.org/10.1074/jbc.M212966200
21. Bader AG, Vogt PK. Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol Cell Biol 2005; 25:2095-106; PMID:15743808; http://dx.doi.org/10.1128/ MCB.25.6.2095-2106.2005
22. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005; 24:4281-92; PMID:15806160; http://dx.doi.org/10.1038/sj.onc.1208590
23. Sorokin AV, Selyutina AA, Skabkin MA, Guryanov SG, Nazimov IV, Richard C, Th'ng J, Yau J, Sorensen PH, Ovchinnikov LP, et al. Proteasomemediated cleavage of the Y-box-binding protein 1 is linked to DNA damage stress response. EMBO J 2005; 24:3602-12; PMID:16193061; http://dx.doi.org/10.1038/sj.emboj.7600830
24. Shibao K, Takano H, Nakayama Y, Okazaki K, Nagata N, Izumi H, Uchiumi T, Kuwano M, Kohno K, Itoh H. Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer 1999; 83:732-7; PMID:10597187; http://dx.doi.org/10.1002/(SICI)1097-0215(19991210)83: 6 <732: :AIDIJC6>3.0.CO;2-#
25. Bergmann S, Royer-Pokora B, Fietze E, Jürchott K, Hildebrandt B, Trost D, Leenders F, Claude JC, Theuring F, Bargou R, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005; 65:4078-87; PMID:15899797; http://dx.doi.org/10.1158/0008-5472.CAN-04-4056
26. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15:402-15; PMID:19411069; http://dx.doi.org/10.1016/j.ccr.2009.03.017
27. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273:5858-68; PMID:9488723; http://dx.doi.org/10.1074/jbc.273.10.5858
28. Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 2002; 12:162-9; PMID:11893489; http://dx.doi.org/10.1016/S0959-437X(02)00282-4
29. Sorokin AV, Kim ER, Ovchinnikov LP. Proteasome system of protein degradation and processing. Biochemistry (Mosc) 2009; 74:1411-42; PMID:20210701; http://dx.doi.org/10.1134/S000629790913001X
30. Rogers SW, Rechsteiner MC. Microinjection studies on selective protein degradation: relationships between stability, structure, and location. Biomed Biochim Acta 1986; 45:1611-8; PMID:3579880
31. Rechsteiner M. Natural substrates of the ubiquitin proteolytic pathway. Cell 1991; 66:615-8; PMID:1652366; http://dx.doi.org/10.1016/0092-8674(91)90104- 7
32. Ghoda L, van Daalen Wetters T, Macrae M, Ascherman D, Coffino P. Prevention of rapid intracellular degradation of ODC by a carboxylterminal truncation. Science 1989; 243:1493-5; PMID:2928784; http://dx.doi.org/10.1126/ science.2928784
33. Kim JE, Minter-Dykhouse K, Chen J. Signaling networks controlled by the MRN complex and MDC1 during early DNA damage responses. Mol Carcinog 2006; 45:403-8; PMID:16691596; http://dx.doi.org/10.1002/mc.20221
34. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000; 10:886-95; PMID:10959836; http://dx.doi.org/10.1016/S0960-9822(00)00610-2
35. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in nonsmall cell lung cancer. Clin Cancer Res 2001; 7:3151-5; PMID:11595709
36. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jürchott K, Schmitt M, Royer HD. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002; 97:278-82; PMID:11774277; http://dx.doi.org/10.1002/ijc.1610
37. Rubinstein DB, Stortchevoi A, Boosalis M, Ashfaq R, Guillaume T. Overexpression of DNA binding protein B gene product in breast cancer as detected by in vitro-generated combinatorial human immunoglobulin libraries. Cancer Res 2002; 62:4985-91; PMID:12208750
38. Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K, Kuwano M, Nakano H. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 2002; 128:621-6; PMID:12458343; http://dx.doi.org/10.1007/s00432-002-0386-6
39. Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett 2003; 190:191-7; PMID:12565174; http://dx.doi.org/10. 1016/S0304-3835(02)00590-6
40. Giménez-Bonafé P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004; 59:337-49; PMID:15042610; http://dx.doi.org/10.1002/pros.20023
41. Yasen M, Kajino K, Kano S, Tobita H, Yamamoto J, Uchiumi T, Kon S, Maeda M, Obulhasim G, Arii S, et al. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res 2005; 11:7354-61; PMID:16243807; http://dx.doi.org/10.1158/1078-0432.CCR-05-1027
42. Schittek B, Psenner K, Sauer B, Meier F, Iftner T, Garbe C. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 2007; 120:2110-8; PMID:17266041; http://dx.doi.org/10.1002/ijc.22512
43. Xu W, Zhou L, Qin R, Tang H, Shen H. Nuclear expression of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome. Eur J Haematol 2009; 83:313-9; PMID:19500133; http://dx.doi.org/10. 1111/j.1600-0609.2009.01285.x
44. Shibahara K, Uchiumi T, Fukuda T, Kura S, Tominaga Y, Maehara Y, Kohno K, Nakabeppu Y, Tsuzuki T, Kuwano M. Targeted disruption of one allele of the Y-box binding protein-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C. Cancer Sci 2004; 95:348-53; PMID:15072594; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03214.x
45. Chatterjee M, Rancso C, Stühmer T, Eckstein N, Andrulis M, Gerecke C, Lorentz H, Royer HD, Bargou RC. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 2008; 111:3714-22; PMID:18006704; http://dx.doi.org/10.1182/ blood-2007-05-089151
46. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y, et al. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009; 69:3148-56; PMID:19318582; http://dx.doi.org/10.1158/0008-5472.CAN-08-2334
47. Gao Y, Fotovati A, Lee C, Wang M, Cote G, Guns E, Toyota B, Faury D, Jabado N, Dunn SE. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Mol Cancer Ther 2009; 8:3276-84; PMID:19996271; http://dx.doi.org/10.1158/1535-7163.MCT-09-0478
48. To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 2010; 70:2840-51; PMID:20332234; http://dx.doi.org/10. 1158/0008-5472.CAN-09-3155
49. Stenina OI, Shaneyfelt KM, DiCorleto PE. Thrombin induces the release of the Y-box protein dbpB from mRNA: a mechanism of transcriptional activation. Proc Natl Acad Sci U S A 2001; 98:7277-82; PMID:11390977; http://dx.doi.org/10. 1073/ pnas.121592298
50. Guay D, Evoy AA, Paquet E, Garand C, Bachvarova M, Bachvarov D, Lebel M. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures. Int J Biochem Cell Biol 2008; 40:2492-507; PMID:18571458; http://dx.doi.org/10.1016/ j.biocel.2008.04.011
51. Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M, Kohno K. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998; 273:5997-6000; PMID:9497311; http://dx.doi.org/10.1074/ jbc.273.11.5997
52. Kaszubiak A, Kupstat A, Müller U, Hausmann R, Holm PS, Lage H. Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1. Biochem Biophys Res Commun 2007; 357:295-301; PMID:17418094; http://dx.doi.org/10.1016/j.bbrc.2007.03.145
53. Evdokimova VM, Wei CL, Sitikov AS, Simonenko PN, Lazarev OA, Vasilenko KS, Ustinov VA, Hershey JW, Ovchinnikov LP. The major protein of messenger ribonucleoprotein particles in somatic cells is a member of the Y-box binding transcription factor family. J Biol Chem 1995; 270:3186-92; PMID:7852402; http://dx.doi.org/10.1074/jbc.270.7.3186
54. Davydova EK, Evdokimova VM, Ovchinnikov LP, Hershey JW. Overexpression in COS cells of p50, the major core protein associated with mRNA, results in translation inhibition. Nucleic Acids Res 1997; 25:2911-6; PMID:9207042; http://dx.doi.org/10.1093/nar/25.14.2911
55. Sorokin AV, Chen J. MEMO1, a new IRS1-interacting protein, induces epithelial-mesenchymal transition in mammary epithelial cells. Oncogene 2013; 32:3130-8; PMID:22824790; http://dx.doi.org/10.1038/ onc.2012.327
56. Adam SA, Marr RS, Gerace L. Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors. J Cell Biol 1990; 111:807-16; PMID:2391365; http://dx.doi.org/10.1083/ jcb.111.3.807